Overview
Ipamorelin features several unique structural modifications, including the presence of 2-naphthylalanine (2-Nal) and D-amino acids, which contribute to its stability and receptor selectivity. The peptide is metabolized primarily through peptidase enzymes and eliminated through renal excretion, with metabolites detectable for up to 24 hours post-administration.
Chemical structure & Properties
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 Da
Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Half-life: Approximately 2 hours (plasma elimination)
Stability: Stable in aqueous solution when refrigerated, susceptible to degradation at room temperature
Regulatory Status and
Legal Considerations
FDA Status
Classification: Investigational new drug (IND) - not approved for therapeutic use
Approval Status: No FDA approval for human clinical applications
Research Use: Limited to approved clinical trials and research protocols
Regulatory Position: Dual status as of April 22, 2026: (1) Nominated but Withdrawn from Category 2 for 503A compounding pharmacies. (2) Still listed on the active Category 2 table for 503B outsourcing facilities — 503B compounding remains prohibited. Consult FDA guidance and legal counsel to confirm which pathway applies.
WADA Status
Classification: Prohibited under S2: Peptide Hormones, Growth Factors
Athletic Use: Banned in competitive sports
Testing: Detectable through specialized anti-doping analysis
Violation Consequences: Subject to sporting sanctions and disqualification
Legal Availability
Commercial Status: Not legally available as prescription medication
Market Presence: Available through research chemical suppliers
Quality Control: No regulatory oversight ensuring purity or potency
Clinical Use: Restricted to research institutions and approved clinical trials
The Paragon Method: Step-by-Step
Clinical Considerations
Important Guidelines:
No FDA-approved dosing recommendations exist
Individual response varies significantly based on age, health status, and baseline GH levels
Medical supervision strongly recommended for any therapeutic application
Regular monitoring of IGF-1 levels and metabolic parameters advised
Quality and authenticity of research chemicals cannot be guaranteed
Priority Research Areas
Clinical Development Priorities:
Large-scale, long-term randomized controlled trials for safety and efficacy
Standardized dosing protocols for specific therapeutic indications
Comprehensive safety evaluation including carcinogenicity studies
Drug interaction studies with commonly prescribed medications
Optimal treatment duration and cycling protocols
Emerging Applications
Investigational Uses:
Post-surgical recovery and wound healing enhancement
Age-related cognitive decline and neuroprotection
Metabolic syndrome and type 2 diabetes management
Osteoporosis prevention and treatment
Chronic fatigue syndrome and fibromyalgia
HIV-associated wasting and muscle atrophy
Combination Therapies
Synergistic Research:
Combination with CJC-1295 for prolonged GH elevation
Integration with exercise and nutritional interventions
Potential combination with other regenerative peptides
Synergistic effects with hormone replacement therapies
Conclusion
Ipamorelin represents a promising and selective growth hormone secretagogue with demonstrated potential in anti-aging, body composition improvement, and metabolic enhancement. Its favorable selectivity profile, minimal side effects, and physiological hormone stimulation distinguish it from other peptides in its class.
However, the current clinical evidence base remains limited, with most data derived from small-scale, short-term studies. The lack of FDA approval, regulatory restrictions, and limited long-term safety data necessitate careful consideration and medical supervision for any therapeutic application.
Patients considering ipamorelin therapy should engage in thorough discussions with qualified healthcare providers to weigh potential benefits against risks and explore evidence-based treatment alternatives. Future research will be critical in determining ipamorelin's role in clinical medicine, particularly in healthy aging, metabolic disorders, and regenerative medicine applications. Until comprehensive clinical trials are completed, its use should remain limited to research settings under appropriate medical oversight.
IPAMORELIN SCIENTIFIC
DATA SUMMARY
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
711.85 Da
5 residues
~2 hours (plasma)
High subcutaneous, poor oral
Up to 24 hours (plasma/urine)
Application
GH Stimulation
Body Composition
Sleep Enhancement
Bone Density
Studies
12+ studies
8+ studies
5+ studies
6+ studies
Dose Range
0.1-3.0 μg/kg
100-300 μg/dose
100-200 μg
1-2 μg/kg
Outcome
3-15x GH increase, selective GHSR activation
Increased lean mass, reduced adiposity
Improved slow-wave sleep, sleep efficiency
Enhanced osteoblast activity, BMD increase
Study Type
Phase I Safety
Body Composition RCT
Sleep Quality Study
Population
24 healthy elderly
32 GH deficient adults
45 middle-aged adults
Results
Significant GH increase, no cortisol elevation
Increased lean mass, IGF-1 levels
Improved sleep efficiency scores
Limitations
Single-dose study, small sample
Short duration (16 weeks)
Subjective measures, no PSG
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
No serious adverse events at therapeutic doses
No significant changes in laboratory parameters
Mild injection site reactions, rare GI upset
Limited human data beyond 16 weeks
Authority
FDA
WADA
DEA
Classification
Investigational New Drug
S2 Peptide Hormones
Unscheduled
Status
Not approved for human use
Prohibited in sports
Not controlled substance
Peptides work best as one part of a complete, medically supervised plan. These are often used alongside our medically supervised weight loss program in Atlanta. To see how this fits your goals, explore our full approach to peptide therapy in Atlanta.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Ipamorelin is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.
The content reflects current scientific literature and regulatory status as of April 22–23, 2026. Note: Ipamorelin acetate has a dual 503A/503B status — see FDA Status section above.
Explore Peptide Therapy at Paragon
Peptides work best as part of a bigger plan, not on their own. At Paragon Sports Medicine in Atlanta, every peptide is prescribed by our team, guided by your labs and your goals, and matched to the right protocol for you. If you are wondering whether this one fits where you want to go, our peptide therapy program in Atlanta is the place to start.